<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04884906</url>
  </required_header>
  <id_info>
    <org_study_id>E20210044</org_study_id>
    <nct_id>NCT04884906</nct_id>
  </id_info>
  <brief_title>Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer</brief_title>
  <official_title>A Single-arm, Single-center, Open, Prospective Phase II Clinical Study of Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effectiveness and safety of camrelizumab combined with radiotherapy and&#xD;
      chemotherapy for recurrent or metastatic cervical cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single-arm, single-center, open, prospective phase II clinical study, the&#xD;
      main purpose of which is to evaluate the effectiveness and safety of camrelizumab combined&#xD;
      with radiotherapy and chemotherapy for recurrent or metastatic cervical cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>2 year</time_frame>
    <description>The objective remission rate refers to the proportion of patients whose tumors have shrunk to a certain amount and maintained for a certain period of time, including cases of complete remission and partial remission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival（PFS）</measure>
    <time_frame>2 year</time_frame>
    <description>The period of time between when a patient with neoplastic disease receives treatment and when the disease progresses or death from any cause occurs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival（OS）</measure>
    <time_frame>2 year</time_frame>
    <description>The time from the patient's confirmation of the disease to death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate（DCR）</measure>
    <time_frame>2 year</time_frame>
    <description>Refers to the proportion of patients whose tumors have shrunk or stabilized for a certain period of time, including complete remission (CR), partial remission (PR) and stable (SD) cases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reaction rate</measure>
    <time_frame>2 year</time_frame>
    <description>Harmful and unrelated reactions that occur when normal doses of drugs are used to prevent, diagnose, treat diseases or regulate physiological functions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient quality of life</measure>
    <time_frame>2 year</time_frame>
    <description>Comprehensively evaluate the pros and cons of life by filling in the questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Locally Advanced Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Camrelizumab combined with radiotherapy and chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>200mg/m2, iv, d1, Q3W, a total of 6 cycles</description>
    <arm_group_label>Camrelizumab combined with radiotherapy and chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>1.8-2.15Gy/time (radiotherapy started on the 8th day of camrelizumab treatment), a total of 28 times (5 times a week), a total of 50.4-60.2Gy.</description>
    <arm_group_label>Camrelizumab combined with radiotherapy and chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albumin Paclitaxel</intervention_name>
    <description>260mg/m2, iv, d1, Q3W, a total of 6 cycles</description>
    <arm_group_label>Camrelizumab combined with radiotherapy and chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>80-120mg/m2, iv, d1-3, Q3W, a total of 6 cycles</description>
    <arm_group_label>Camrelizumab combined with radiotherapy and chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years old and ≤75 years old;&#xD;
&#xD;
          2. ECOG score 0-1 level;&#xD;
&#xD;
          3. Cervical cancer diagnosed pathologically, cervical cancer that has recurred or&#xD;
             metastasized after at least first-line chemotherapy or surgery;&#xD;
&#xD;
          4. Genetic testing: PD-L1≥1%;&#xD;
&#xD;
          5. The expected survival period is ≥6 months;&#xD;
&#xD;
          6. The functional level of major organs must meet the following requirements:&#xD;
&#xD;
             Blood routine: ANC≥1.5×109/L; PLT≥90×109/L; Hb≥90 g/L; Blood biochemistry:&#xD;
             TBIL≤2.5×ULN; ALT and AST≤1.5×ULN; BUN and Cr ≤1.5×ULN;&#xD;
&#xD;
          7. Heart color Doppler ultrasound: LVEF≥50%;&#xD;
&#xD;
          8. 12-lead electrocardiogram: QT interval (QTcF) corrected by Fridericia method &lt;450 ms&#xD;
             for males and &lt;470 ms for females;&#xD;
&#xD;
          9. No blood transfusion within 2 weeks before screening;&#xD;
&#xD;
         10. For female subjects who have not undergone menopause or have not undergone surgical&#xD;
             sterilization, during the treatment period and at least 7 months after the last&#xD;
             administration in the study treatment, agree to abstain from sex or use an effective&#xD;
             method of contraception;&#xD;
&#xD;
         11. Volunteer to join the study, sign informed consent, have good compliance and are&#xD;
             willing to cooperate with follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have received previous anti-tumor therapy or radiotherapy for any malignant tumor,&#xD;
             excluding cured cervical carcinoma in situ, basal cell carcinoma or squamous cell&#xD;
             carcinoma and other malignant tumors;&#xD;
&#xD;
          2. Previously received camrelizumab or other PD-1/PD-L1 treatments and cannot be included&#xD;
             in the group; the subject is known to have been exposed to macromolecular protein&#xD;
             preparations, or is known to be against any carrelizumab, or Subjects are allergic to&#xD;
             the chemotherapeutic ingredients used during neoadjuvant treatment;&#xD;
&#xD;
          3. At the same time receive anti-tumor therapy in other clinical trials, including&#xD;
             endocrine therapy, bisphosphonate therapy or immunotherapy;&#xD;
&#xD;
          4. In the 4 weeks before randomization, have received major surgical operations not&#xD;
             related to cervical cancer, or the subject has not fully recovered from such surgical&#xD;
             operations.&#xD;
&#xD;
          5. Those who are known to have a history of allergies to the drug components of this&#xD;
             program;&#xD;
&#xD;
          6. A history of immunodeficiency, including a positive HIV test, or other acquired or&#xD;
             congenital immunodeficiency diseases, or a history of organ transplantation.&#xD;
&#xD;
          7. Have ever suffered from any heart disease, including: (1) angina pectoris; (2)&#xD;
             arrhythmia requiring medical treatment or clinical significance; (3) myocardial&#xD;
             infarction; (4) heart failure; (5) any investigator Other heart diseases judged to be&#xD;
             unsuitable for participating in this test.&#xD;
&#xD;
          8. Female patients during pregnancy and lactation, female patients with fertility and a&#xD;
             positive baseline pregnancy test, or female patients of childbearing age who are&#xD;
             unwilling to take effective contraceptive measures during the entire trial period.&#xD;
&#xD;
          9. According to the judgment of the investigator, there are concomitant diseases&#xD;
             (including but not limited to high blood pressure, severe diabetes, active infection,&#xD;
             thyroid disease, etc.) that seriously endanger the safety of the patient or affect the&#xD;
             completion of the study;&#xD;
&#xD;
         10. Inability to swallow, chronic diarrhea and intestinal obstruction, there are many&#xD;
             factors that affect the administration and absorption of drugs.&#xD;
&#xD;
         11. The researcher believes that the subject is not suitable for participating in any&#xD;
             other situations in this research.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chen</last_name>
  </overall_contact>
  <location>
    <facility>
      <name>TianjinCIH</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen Zhongjie</last_name>
      <phone>18622228638</phone>
      <email>13702096685@139.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 11, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

